Company: BIAF
Filing Date: 2025-05-07
Form Type: 424B4
Source: 0001641172-25-008977
Chunk: 2

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-07
Form: 424B4
Chunk 2
---
 of an Anti-Dilution Adjustment (as further described under “Description of the Securities We Are Offering:” (b) the Stockholder Approval Notice Date; and (c) the effective date of the filingof the Certificate of Amendment . Based on an initial exercise price of $0.352 per share (equal to 110% of the combined offering price per Share and accompanying May 2025 Warrant), if a reverse stock split is effected an additional 4,570,312 shares of Common Stock (on a pre-reverse stock split basis which number shall be adjusted based on the reverse stock split ratio) will be issuable upon exercise of the May 2025 Warrants and then, subject to obtaining Warrant Stockholder Approval, if a subsequent offering occurs for which the exercise price of the May 2025 Warrants is reset to the floor price of $0.10 per share, an additional 49,907,811 (on a pre-reverse stock split basis which number shall be adjusted based on the reverse stock split ratio) shares of Common Stock would be issuable upon exercise of the May 2025 Warrants.

We are also offering to those purchasers, if any, whose purchase of shares of Common Stock in this offering would result in such purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding Common Stock following the consummation of this offering, the opportunity to purchase, in lieu of the shares of our Common Stock that would otherwise result in the purchaser’s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%), Pre-Funded Warrants each to purchase one share of Common Stock at an exercise price of $0.007 per share. Each Pre-Funded Warrant is being issued together with one May 2025 Warrant to purchase one and one-half share of Common Stock. The combined public offering price for each Pre-Funded Warrant and accompanying May 2025 Warrant will be equal to the public offering price per share of Common Stock and accompanying May 2025 Warrant in this offering, minus $0.007. Each Pre-Funded Warrant will be exercisable upon issuance and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full.

This prospectus also relates to the offering of the shares of Common Stock issuable upon exercise of the Pre-Funded